Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Prabhu S. Arunachalam,Alexandra C. Walls,Nadia A. Golden,Caroline Atyeo,Stephanie Fischinger,Chunfeng Li,Pyone P. Aye,Mary Jane Navarro,Lilin Lai,Venkata Viswanadh Edara,Katharina Röltgen,Kenneth A. Rogers,Lisa Shirreff,Douglas E. Ferrell,Samuel Wrenn,Deleah Pettie,John C. Kraft,Marcos C. Miranda,Elizabeth Kepl,Claire Sydeman,Natalie Brunette,Michael E. P. Murphy,Brooke Fiala,Lauren Carter,Alexander G. White,Meera Trisal,Ching-Lin Hsieh,Kasi E. Russell-Lodrigue,Christopher Monjure,Jason Dufour,Skye Spencer,Lara A. Doyle-Meyers,Rudolph Bohm,Nicholas J. Maness,Chad J. Roy,Jessica A. Plante,Kenneth S. Plante,Alex Lee Zhu,Matthew J. Gorman,Sally Shin,Xiaoying Shen,Jane Fontenot,Shakti Gupta,Derek T. O'Hagan,Robbert van der Most,Rino Rappuoli,Robert L. Coffman,David Novack,Jason S. McLellan,Shankar Subramaniam,David C. Montefiori,Scott D. Boyd,JoAnne L. Flynn,Galit Alter,Francois Villinger,Harry Kleanthous,Jay Rappaport,Mehul S. Suthar,Neil P. King,Neil P. King,David Veesler,Bali Pulendran +61 more
TLDR
In this article, the authors demonstrate the capacity of a subunit vaccine, comprising the SARS-CoV-2 spike protein receptor-binding domain displayed on an I53-50 protein nanoparticle scaffold (hereafter designated RBD-NP), to stimulate robust and durable neutralizing-antibody responses.Abstract:
The development of a portfolio of COVID-19 vaccines to vaccinate the global population remains an urgent public health imperative1. Here we demonstrate the capacity of a subunit vaccine, comprising the SARS-CoV-2 spike protein receptor-binding domain displayed on an I53-50 protein nanoparticle scaffold (hereafter designated RBD-NP), to stimulate robust and durable neutralizing-antibody responses and protection against SARS-CoV-2 in rhesus macaques. We evaluated five adjuvants including Essai O/W 1849101, a squalene-in-water emulsion; AS03, an α-tocopherol-containing oil-in-water emulsion; AS37, a Toll-like receptor 7 (TLR7) agonist adsorbed to alum; CpG1018-alum, a TLR9 agonist formulated in alum; and alum. RBD-NP immunization with AS03, CpG1018-alum, AS37 or alum induced substantial neutralizing-antibody and CD4 T cell responses, and conferred protection against SARS-CoV-2 infection in the pharynges, nares and bronchoalveolar lavage. The neutralizing-antibody response to live virus was maintained up to 180 days after vaccination with RBD-NP in AS03 (RBD-NP-AS03), and correlated with protection from infection. RBD-NP immunization cross-neutralized the B.1.1.7 SARS-CoV-2 variant efficiently but showed a reduced response against the B.1.351 variant. RBD-NP-AS03 produced a 4.5-fold reduction in neutralization of B.1.351 whereas the group immunized with RBD-NP-AS37 produced a 16-fold reduction in neutralization of B.1.351, suggesting differences in the breadth of the neutralizing-antibody response induced by these adjuvants. Furthermore, RBD-NP-AS03 was as immunogenic as a prefusion-stabilized spike immunogen (HexaPro) with AS03 adjuvant. These data highlight the efficacy of the adjuvanted RBD-NP vaccine in promoting protective immunity against SARS-CoV-2 and have led to phase I/II clinical trials of this vaccine (NCT04742738 and NCT04750343).read more
Citations
More filters
Journal ArticleDOI
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
David Veesler,Eakapol Wankahart,Djoʻrayeva Faridaxon Egamberdiyevna,Qayumova Margʻubaxon Egamberdiyevna,Julie Grangeon +3 more
TL;DR: In this paper , the authors determined the crystal structures of the spike protein and the receptor-binding domain bound to the broadly neutralizing sarbecovirus monoclonal antibody (mAb) S309 (the parent mAb of sotrovimab) and to the human ACE2 receptor.
Journal ArticleDOI
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern.
Matthew McCallum,Jessica Bassi,Anna De Marco,Alexander Chen,Alexandra C. Walls,Julia di Iulio,M. Alejandra Tortorici,Mary-Jane Navarro,Chiara Silacci-Fregni,Christian Saliba,Kaitlin R. Sprouse,Maria De Agostini,Dora Pinto,Katja Culap,Siro Bianchi,Stefano Jaconi,Elisabetta Cameroni,John E. Bowen,Sasha W Tilles,Matteo Samuele Pizzuto,Sonja Bernasconi Guastalla,Giovanni Bona,Alessandra Franzetti Pellanda,Christian Garzoni,Wesley C. Van Voorhis,Laura E. Rosen,Gyorgy Snell,Amalio Telenti,Herbert W. Virgin,Luca Piccoli,Davide Corti,David Veesler +31 more
TL;DR: In this paper, a novel variant of concern (VOC) named CAL.20C (B.1.427/B. 1.429), which was originally detected in California, carries spike glycoprotein mutations S13I in the signal peptide, W152C in the N-terminal domain (NTD), and L452R in the receptor-binding domain (RBD).
Journal ArticleDOI
Tackling COVID-19 with neutralizing monoclonal antibodies
TL;DR: An overview of SARS-CoV-2-neutralizing mAbs, including their origin, specificity, structure, antiviral and immunological mechanisms of action, and resistance to circulating variants, as well as a snapshot of the clinical trials of approved or late-stage mAb therapeutics can be found in this paper.
Journal ArticleDOI
Systems vaccinology of the BNT162b2 mRNA vaccine in humans.
Prabhu S. Arunachalam,Madeleine K D Scott,Thomas Hagan,Thomas Hagan,Chunfeng Li,Yupeng Feng,Florian Wimmers,Lilit Grigoryan,Meera Trisal,Venkata Viswanadh Edara,Lilin Lai,Sarah Esther Chang,Allan Feng,Shaurya Dhingra,Mihir Shah,Alexandra S. Lee,Sharon Chinthrajah,Sayantani B. Sindher,Vamsee Mallajosyula,Fei Gao,Natalia Sigal,Sangeeta Kowli,Sheena Gupta,Kathryn L. Pellegrini,Gregory K. Tharp,Sofia Maysel-Auslender,Sydney Hamilton,Hadj Aoued,Kevin Hrusovsky,Mark Roskey,Steven E. Bosinger,Steven E. Bosinger,Holden T. Maecker,Scott D. Boyd,Mark M. Davis,Paul J. Utz,Mehul S. Suthar,Purvesh Khatri,Kari C. Nadeau,Kari C. Nadeau,Bali Pulendran +40 more
TL;DR: In this article, the authors used a system vaccinology approach to comprehensively profile the innate and adaptive immune responses of 56 healthy volunteers who were vaccinated with the Pfizer-BioNTech mRNA vaccine (BNT162b2).
Journal ArticleDOI
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.
Brian J. Ward,Philipe Gobeil,Annie Séguin,Judith Atkins,Iohann Boulay,Pierre-Yves Charbonneau,Manon Couture,Marc-André D'Aoust,Jiwanjeet Dhaliwall,Carolyn Finkle,Karen Hager,Asif Mahmood,Alexander I. Makarkov,Matthew P. Cheng,Stéphane Pillet,Patricia Schimke,Sylvie St-Martin,Sonia Trépanier,Nathalie Landry +18 more
TL;DR: In this paper, the authors report Day 42 interim safety and immunogenicity data from an observer-blinded, dose escalation, randomized controlled study of a virus-like particle vaccine candidate produced in plants that displays the SARS-CoV-2 spike glycoprotein (CoVLP: NCT04450004 ).
References
More filters
Journal ArticleDOI
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
Ching-Lin Hsieh,Jory A. Goldsmith,Jeffrey M. Schaub,Andrea M. DiVenere,Hung-Che Kuo,Kamyab Javanmardi,Kevin C. Le,Daniel Wrapp,Alison Gene-Wei Lee,Yutong Liu,Chia Wei Chou,Patrick O. Byrne,Christy K. Hjorth,Nicole V. Johnson,John Ludes-Meyers,Annalee W. Nguyen,Juyeon Park,Nianshuang Wang,Dzifa Amengor,Jason J. Lavinder,Gregory C. Ippolito,Jennifer A. Maynard,Ilya J. Finkelstein,Jason S. McLellan +23 more
TL;DR: High-yield production of a stabilized prefusion spike protein will accelerate the development of vaccines and serological diagnostics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Journal ArticleDOI
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.
Noe B. Mercado,Roland Zahn,Frank Wegmann,Carolin Loos,Carolin Loos,Abishek Chandrashekar,Jingyou Yu,Jinyan Liu,Lauren Peter,Katherine McMahan,Lisa H. Tostanoski,Xuan He,David R. Martinez,Lucy Rutten,Rinke Bos,Danielle van Manen,Jort Vellinga,Jerome Custers,Johannes P. M. Langedijk,Ted Kwaks,Mark J. G. Bakkers,David Zuijdgeest,Sietske K. Rosendahl Huber,Caroline Atyeo,Caroline Atyeo,Stephanie Fischinger,Stephanie Fischinger,John S. Burke,Jared Feldman,Jared Feldman,Blake M. Hauser,Blake M. Hauser,Timothy M. Caradonna,Timothy M. Caradonna,Esther A. Bondzie,Gabriel Dagotto,Gabriel Dagotto,Makda S. Gebre,Makda S. Gebre,Emily Hoffman,Catherine Jacob-Dolan,Catherine Jacob-Dolan,Marinela Kirilova,Zhenfeng Li,Zijin Lin,Shant H. Mahrokhian,Lori F. Maxfield,Felix Nampanya,Ramya Nityanandam,Joseph P. Nkolola,Shivani A. Patel,John D. Ventura,Kaylee Verrington,Huahua Wan,Laurent Pessaint,Alex Van Ry,Kelvin Blade,Amanda Strasbaugh,Mehtap Cabus,Renita Brown,Anthony L. Cook,Serge Zouantchangadou,Elyse Teow,Hanne Andersen,Mark G. Lewis,Yongfei Cai,Bing Chen,Aaron G. Schmidt,Aaron G. Schmidt,R. Keith Reeves,Ralph S. Baric,Douglas A. Lauffenburger,Galit Alter,Paul Stoffels,Mathai Mammen,Johan Van Hoof,Hanneke Schuitemaker,Dan H. Barouch +77 more
TL;DR: Robust single-shot vaccine protection against SARS-CoV-2 in nonhuman primates is demonstrated and vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection.
Journal ArticleDOI
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
Alicia T. Widge,Nadine Rouphael,Lisa A. Jackson,Evan J. Anderson,Paul C. Roberts,Mamodikoe Makhene,James D. Chappell,Mark R. Denison,Laura J. Stevens,Andrea J. Pruijssers,Adrian B. McDermott,Britta Flach,Bob C. Lin,Nicole A. Doria-Rose,Sijy O'Dell,Stephen D. Schmidt,Kathleen M. Neuzil,Hamilton Bennett,Brett Leav,Mat Makowski,Jim Albert,Kaitlyn Cross,Venkata Viswanadh Edara,Katharine Floyd,Mehul S. Suthar,Wendy Buchanan,Catherine J. Luke,Julie E. Ledgerwood,John R. Mascola,Barney S. Graham,John H. Beigel +30 more
TL;DR: A small number of adults received two 100-μg injections of Moderna’s mRNA SARS-CoV-2 vaccine, and serum anti–spike protein and neutralizing antibody titers revealed immunogenicity and safety concerns.
Journal ArticleDOI
Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays.
Katharine H.D. Crawford,Katharine H.D. Crawford,Rachel Eguia,Adam S. Dingens,Andrea N. Loes,Keara D. Malone,Caitlin R Wolf,Helen Y. Chu,M. Alejandra Tortorici,M. Alejandra Tortorici,David Veesler,Michael L. M. Murphy,Deleah Pettie,Neil P. King,Alejandro B. Balazs,Jesse D. Bloom,Jesse D. Bloom,Jesse D. Bloom +17 more
TL;DR: It is demonstrated how these pseudotyped lentiviral particles could be used to measure the neutralizing activity of human sera or plasma against SARS-CoV-2 in convenient luciferase-based assays, thereby providing a valuable complement to ELISA-based methods that measure antibody binding rather than neutralization.
Journal ArticleDOI
An infectious cDNA clone of SARS-CoV-2
Xuping Xie,Antonio E. Muruato,Kumari G. Lokugamage,Krishna Narayanan,Xianwen Zhang,Jing Zou,Jianying Liu,Craig Schindewolf,Nathen E. Bopp,Patricia V. Aguilar,Kenneth S. Plante,Scott C. Weaver,Shinji Makino,James W. LeDuc,Vineet D. Menachery,Pei Yong Shi +15 more
TL;DR: The reverse genetic system and reporter virus provide key reagents to study SARS-CoV-2 and develop countermeasures and were successfully used to evaluate the antiviral activities of interferon (IFN).
Related Papers (5)
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou,Xing-Lou Yang,Xian Guang Wang,Ben Hu,Lei Zhang,Wei Zhang,Hao Rui Si,Yan Zhu,Bei Li,Chao Lin Huang,Hui-Dong Chen,Jing Chen,Yun Luo,Hua Guo,Ren Di Jiang,Meiqin Liu,Ying Chen,Xu Rui Shen,Xi Wang,Xiao Shuang Zheng,Kai Zhao,Quanjiao Chen,Fei Deng,Lin Lin Liu,Bing Yan,Fa Xian Zhan,Yan-Yi Wang,Gengfu Xiao,Zhengli Shi +28 more